RareSearch logo

Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Pauline Schiller profile

Pauline Schiller

🇮🇩 Indonesia

9.3

    Reviewed:

  • - Project Management
  • - 10 weeks July - September 2023
  • - Biotech Company

Seamless project management, results exceeded expectations.

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Isabel Mosciski profile

Isabel Mosciski

🇨🇦 Canada

9.1

    Reviewed:

  • - Clinical Data Management
  • - 6 weeks June - July 2023
  • - CRO

Timely and accurate data management, great collaboration.

The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.

Joy Mills DVM profile

Joy Mills DVM

🇦🇺 Australia

8.9

    Reviewed:

  • - Stability Studies
  • - 18 months January 2023 - June 2024
  • - Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Jane Purdy-Nitzsche profile

Jane Purdy-Nitzsche

🇩🇪 Germany

9.2

    Reviewed:

  • - Regulatory Strategy Consulting
  • - 4 weeks July - August 2024
  • - Biotech Startup

Thorough and strategic regulatory strategy consulting.

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Leticia Russel profile

Leticia Russel

🇯🇵 Japan

9.3

    Reviewed:

  • - Market Access Strategy
  • - 6 weeks January - February 2024
  • - Pharmaceutical Company

Strategic market access analysis, insightful recommendations.

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Tom Leffler IV profile

Tom Leffler IV

🇩🇪 Germany

9.4

    Reviewed:

  • - Health Technology Assessment
  • - 10 weeks September - November 2023
  • - Pharmaceutical Company

Thorough and insightful health technology assessment.

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Dr. Neal Gleason profile

Dr. Neal Gleason

🇪🇸 Spain

6.5

    Reviewed:

  • - Regulatory Submission
  • - 8 weeks May - July 2024
  • - Pharmaceutical Company

Regulatory submission was incomplete, required additional work.

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Rosemary Braun III profile

Rosemary Braun III

🇷🇺 Russia

8.8

    Reviewed:

  • - Biostatistical Design
  • - 4 weeks May - June 2023
  • - Research Institution

Excellent biostatistical support, clear and actionable insights.

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Beth Quitzon profile

Beth Quitzon

🇨🇦 Canada

9

    Reviewed:

  • - Clinical Protocol Design
  • - 6 weeks April - May 2023
  • - Pharmaceutical Company

Comprehensive protocol design, very detailed and precise.

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Roberto Vandervort profile

Roberto Vandervort

🇪🇸 Spain

5.4

    Reviewed:

  • - Process Development
  • - 14 weeks June - September 2024
  • - Biotech Company

Process development project faced delays, communication issues.

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.